question,correct_answer,model_output,extracted_info,correct,urls
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Placebo when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02294461,"Based on a search for pivotal clinical trials comparing Enzalutamide to Placebo in Prostate Cancer, a prominent study is the PREVAIL trial.

NCT01212991",NCT01212991,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Figitumumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00596830,NCT00679172,NCT00679172,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Cisplatin and Gemcitabine (GC) when used to treat Cholangiocarcinoma.
Output it in the format NCT<Number>",NCT00262769,"The clinical trial that best describes the efficacy of Gemcitabine monotherapy compared to Cisplatin and Gemcitabine (GC) when used to treat Cholangiocarcinoma (as part of advanced biliary tract cancers) is the ABC-02 trial.

NCT00265844",NCT00265844,False,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to Goserelin and Tamoxifen when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00309478,"Based on your description of comparing CMF to Goserelin and Tamoxifen for efficacy in breast cancer, the trial that best fits is a large, randomized trial often known as IBCSG Trial VIII.

The clinical trial identifier for this study is:

NCT00002865",NCT00002865,False,
"Find/search the clinical trial id that best describes the efficacy of Abiraterone and Apalutamide compared to Abiraterone monotherapy when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02257736,"Based on searching clinical trial databases for studies comparing Abiraterone + Apalutamide vs. Abiraterone monotherapy for efficacy in prostate cancer, the most relevant trial is the ACIS trial.

NCT02983078",NCT02983078,False,
"Find/search the clinical trial id that best describes the efficacy of Apixaban monotherapy compared to Enoxaparin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00452530,NCT00643291,NCT00643291,False,
"Find/search the clinical trial id that best describes the efficacy of Apixaban monotherapy compared to Enoxaparin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00423319,"Based on a search of clinical trial databases for studies comparing Apixaban and Enoxaparin for the *treatment* of Venous Thromboembolism (VTE) with a focus on efficacy, the pivotal trial is the AMPLIFY study. While the comparator arm used Enoxaparin followed by Warfarin (representing standard care at the time), the Apixaban arm used Apixaban alone after an initial higher dose phase, establishing its efficacy as a simplified/monotherapy strategy against the standard involving initial Enoxaparin.

The clinical trial identifier is:

NCT00642713",NCT00642713,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, Durvalumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03800134,NCT03164616,NCT03164616,False,
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Placebo when used to treat Prostate cancer (Metastatic).
Output it in the format NCT<Number>",NCT00974311,"Based on the search for pivotal clinical trials comparing Enzalutamide to Placebo for efficacy in metastatic prostate cancer, the PREVAIL trial is a key study. It evaluated enzalutamide versus placebo in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). While technically both arms received standard androgen deprivation therapy (ADT), the trial compared the *addition* of enzalutamide versus the *addition* of placebo to ADT, demonstrating the efficacy contribution of enzalutamide.

The Clinical Trial ID for the PREVAIL study is:

NCT01212991",NCT01212991,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) compared to Carboplatin and Paclitaxel (CP) and Penpulimab when used to treat Non-small cell lung cancer squamous (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT03866993,"Based on your criteria, the clinical trial that best describes the efficacy of Carboplatin and Paclitaxel (CP) compared to Carboplatin and Paclitaxel (CP) and Penpulimab in treating locally advanced or metastatic squamous non-small cell lung cancer is:

NCT03786081",NCT03786081,False,
"Find/search the clinical trial id that best describes the efficacy of Alectinib monotherapy compared to Crizotinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT02838420,"The clinical trial id that best describes the efficacy of Alectinib monotherapy compared to Crizotinib monotherapy when used as a first-line treatment for ALK-positive Non-small cell lung cancer is:

NCT02075826",NCT02075826,False,
"Find/search the clinical trial id that best describes the efficacy of Sunitinib monotherapy compared to Everolimus monotherapy when used to treat Non-clear cell renal cell carcinoma.
Output it in the format NCT<Number>",NCT01108445,"Based on searching clinical trial databases for trials comparing Sunitinib monotherapy to Everolimus monotherapy specifically in Non-clear cell renal cell carcinoma and evaluating efficacy, the following trial is the most relevant large-scale study:

NCT00933743",NCT00933743,False,
"Find/search the clinical trial id that best describes the efficacy of Tranexamic acid monotherapy compared to Placebo when used to treat Hereditary hemorrhagic telangiectasia.
Output it in the format NCT<Number>",NCT00355108,"Based on a search of clinical trial databases, the clinical trial that best fits the description of comparing Tranexamic acid monotherapy to Placebo for the efficacy in treating Hereditary Hemorrhagic Telangiectasia (specifically a primary symptom like epistaxis) is:

**NCT00695706**",NCT00695706,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to ABCP when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03991403,"Based on a search of clinical trial databases, I cannot find a specific clinical trial with an NCT number that directly compares the efficacy of Carboplatin and Pemetrexed head-to-head against a regimen explicitly named ""ABCP"" (Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel) for the treatment of Non-Small Cell Lung Cancer.

While Carboplatin/Pemetrexed is a standard regimen, and Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel (often referred to as ABCP) was studied in trials like IMpower150 (NCT02366143), these regimens were typically compared to different control arms, not directly to each other in a single trial designed for that specific comparison.

Therefore, I cannot provide an NCT number for a trial that precisely fits the comparison you described.",NCT02366143,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Rituximab (R2) compared to Rituximab monotherapy when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT01938001,"NCT01949269

This is the ID for the AUGMENT trial, a Phase 3 study comparing Lenalidomide plus Rituximab (R2) versus Rituximab plus Placebo in patients with relapsed/refractory Follicular Lymphoma (among other indolent lymphomas). It directly compares the efficacy of R2 against Rituximab monotherapy.",NCT01949269,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Bevacizumab when used to treat Breast cancer (Not Applicable).
Output it in the format NCT<Number>",NCT00333775,"Based on your description, the clinical trial that best fits the comparison of Docetaxel monotherapy versus Docetaxel plus Bevacizumab for efficacy in breast cancer is the AVADO trial. Although Bevacizumab's approval for this indication was later withdrawn in some regions, this trial specifically investigated that combination.

The ID is:
NCT00097691",NCT00097691,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH) compared to BTH (Docetaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00391092,"Based on your description, the clinical trial that specifically compared Bevacizumab/Docetaxel/Trastuzumab (BTH) to Docetaxel/Trastuzumab (TH) for the treatment of breast cancer to assess efficacy is:

NCT00381882",NCT00381882,False,
"Find/search the clinical trial id that best describes the efficacy of Low-dose Cytarabine monotherapy (LoDAC) compared to Azacitidine monotherapy when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00071799,"Based on a search of clinical trial databases, the pivotal trial that best describes the efficacy comparison involving Azacitidine versus conventional care regimens (which included low-dose Cytarabine as a primary option) in older patients with Acute Myeloid Leukemia is:

NCT00049516",NCT00049516,False,
"Find/search the clinical trial id that best describes the efficacy of Enzalutamide monotherapy compared to Abiraterone and Enzalutamide when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT01949337,"Based on your description, which seems to be asking for a trial comparing Enzalutamide versus Abiraterone in prostate cancer (as ""Abiraterone and Enzalutamide"" together as a comparator to Enzalutamide monotherapy is not a standard comparison), the clinical trial that best fits the comparison of Enzalutamide efficacy against Abiraterone efficacy in prostate cancer is:

NCT02356873

This trial (ENZARA-PC) compared Enzalutamide versus Abiraterone Acetate plus Prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer.",NCT02356873,False,
"Find/search the clinical trial id that best describes the efficacy of Blinatumomab monotherapy compared to Standard salvage consolidation chemotherapy when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT02393859,NCT02101853,NCT02101853,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Paclitaxel (CP) when used to treat Melanoma.
Output it in the format NCT<Number>",NCT02023710,"Based on your criteria, the clinical trial ID that best describes the efficacy comparison of Carboplatin and Paclitaxel (CP) and Bevacizumab (CP+B) versus Carboplatin and Paclitaxel (CP) for treating Melanoma is:

NCT00942757",NCT00942757,False,
"Find/search the clinical trial id that best describes the efficacy of AC-TH (Docetaxel) compared to AC-D when used to treat Breast cancer (Node Positive).
Output it in the format NCT<Number>",NCT00021255,"Based on your description, you are looking for a clinical trial comparing a regimen including Doxorubicin (A), Cyclophosphamide (C), Docetaxel (T), and Trastuzumab (H) (often given sequentially as AC followed by T and H, or AC followed by T+H) against a regimen using only Doxorubicin, Cyclophosphamide, and Docetaxel (AC followed by T), specifically for node-positive breast cancer.

This comparison, particularly in the context of adding Trastuzumab (Herceptin), typically targets HER2-positive breast cancer. The pivotal trial that demonstrated the significant benefit of adding Trastuzumab concurrently with or sequentially after a taxane following AC chemotherapy in this setting (including node-positive patients) is the NSABP B-31 trial (often analyzed in conjunction with NCCTG N9831).

The Clinical Trial ID for NSABP B-31 is:

NCT00004067",NCT00004067,False,
"Find/search the clinical trial id that best describes the efficacy of FOLFIRI and Bevacizumab compared to FOLFIRI when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00720512,"Based on the clinical trial search, a major study that evaluated FOLFIRI and Bevacizumab compared to FOLFIRI (among other regimens) in metastatic colorectal cancer is the **TREE Study**.

The ClinicalTrials.gov identifier for this trial is:
NCT00063951",NCT00063951,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd) and Venetoclax when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT02755597,NCT02755597,NCT02755597,True,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel monotherapy compared to Buparlisib and Paclitaxel when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01852292,NCT01868452,NCT01868452,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT01364012,NCT00006676,NCT00006676,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib and Dexamethasone (Vd) compared to SVd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03110562,"The acronym ""SVd"" is not a standard, widely recognized regimen in Multiple Myeloma. However, a major Phase 3 clinical trial directly compared Bortezomib and Dexamethasone (Vd) to a combination including Bortezomib, Dexamethasone, and Selinexor (XVd). Selinexor starts with 'S', making this trial a strong candidate that fits your description of comparing Vd to ""SVd"" (interpreting 'S' in relation to Selinexor).

This trial is the **BOSTON** study.

NCT03110562",NCT03110562,True,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Vemurafenib monotherapy when used to treat Melanoma.
Output it in the format NCT<Number>",NCT01667419,"Based on searches for pivotal clinical trials comparing Vemurafenib monotherapy against a control group for efficacy in treating Melanoma (specifically BRAF V600 mutated), the trial that best fits the description of establishing efficacy is the BRIM-3 study. While its control arm was Dacarbazine rather than Placebo, it served as the pivotal comparator demonstrating Vemurafenib's significant efficacy compared to the standard of care at the time. A large, direct Placebo-controlled trial for advanced melanoma with Vemurafenib monotherapy is less common after a comparator like Dacarbazine was established.

The clinical trial id for the BRIM-3 study is:

NCT01006918",NCT01006918,False,
"Find/search the clinical trial id that best describes the efficacy of ATRA, Mercaptopurine, Methotrexate compared to ATRA monotherapy when used to treat Acute promyelocytic leukemia.
Output it in the format NCT<Number>",NCT00003934,"Based on searching clinical trial databases for studies comparing ATRA + Mercaptopurine + Methotrexate to ATRA monotherapy specifically in the context of Acute Promyelocytic Leukemia, it is challenging to find a major clinical trial that *directly* uses ATRA monotherapy as the *control arm* against the ATRA + Mercaptopurine + Methotrexate combination, particularly in the maintenance phase where this combination was most prominently used. ATRA monotherapy is generally insufficient for induction or consolidation therapy compared to combinations.

The combination of ATRA + Mercaptopurine + Methotrexate was most notably studied as a *maintenance therapy* following induction and consolidation with ATRA and chemotherapy.

The clinical trial that best describes the *efficacy of the ATRA, Mercaptopurine, Methotrexate combination* in the context of APL, although compared to observation (no maintenance) rather than ATRA monotherapy maintenance, is the APL 97 study conducted by the European APL Group (EORTC-GIMEMA-PETHEMA). This trial established the benefit of maintenance therapy using this regimen.

The ClinicalTrials.gov ID for a study closely related to or representing the APL 97 protocol is:

NCT00002695",NCT00002695,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and nab-Paclitaxel compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT00540514,NCT00789373,NCT00789373,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Ipilimumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00527735,NCT01454739,NCT01454739,False,
"Find/search the clinical trial id that best describes the efficacy of Elo-Vd compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01478048,"Based on a search of major clinical trial databases, there does not appear to be a large, dedicated Phase 3 clinical trial that directly compares Elotuzumab + Bortezomib + Dexamethasone (Elo-Vd) head-to-head against Bortezomib + Dexamethasone (Vd) alone as its primary efficacy endpoint in Multiple Myeloma.

Elotuzumab's efficacy in combination with other agents was primarily established in trials comparing:
*   Elotuzumab + Lenalidomide + Dexamethasone (Elo-Rd) vs. Lenalidomide + Dexamethasone (Rd) in newly diagnosed and relapsed/refractory MM (e.g., ELOQUENT-1 NCT01335399, ELOQUENT-2 NCT01239685).
*   Elotuzumab + Pomalidomide + Dexamethasone (Elo-Pd) vs. Pomalidomide + Dexamethasone (Pd) in relapsed/refractory MM (ELOQUENT-3 NCT02654132).

While Elo-Vd combinations are used and studied in smaller trials or as part of multi-arm studies, a landmark trial specifically comparing Elo-Vd vs. Vd alone is not the primary basis for describing Elotuzumab's comparative efficacy.

Therefore, I cannot provide an NCT number for the specific direct comparative trial you requested because such a trial does not stand out as the primary evidence source for the Elo-Vd vs Vd comparison.",NCT01335399,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel, nanoparticle albumin-bound and Bevacizumab compared to Paclitaxel and Bevacizumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00785291,"Based on your description, the clinical trial that directly compares the efficacy of nab-paclitaxel (nanoparticle albumin-bound paclitaxel) plus Bevacizumab to conventional Paclitaxel plus Bevacizumab in treating breast cancer, particularly in the metastatic setting, is:

NCT00700859",NCT00700859,False,
"Find/search the clinical trial id that best describes the efficacy of T-ddAC compared to T-ddAC and Bevacizumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00861705,"Based on the description comparing a dose-dense Adriamycin, Cyclophosphamide, and Taxane (T-ddAC) regimen alone versus the same regimen with Bevacizumab for breast cancer efficacy, the clinical trial that best fits this description is ECOG E5103.

The ClinicalTrials.gov identifier for this trial is:

NCT00433511",NCT00433511,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Lenalidomide and Rituximab (R2) when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00238238,"Based on your criteria, the clinical trial that best describes the efficacy comparison between Lenalidomide monotherapy and Lenalidomide and Rituximab (R2) in Follicular Lymphoma (as part of relapsed/refractory indolent B-cell lymphoma) is:

NCT01899876",NCT01899876,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Gemcitabine (GC) and Bevacizumab compared to Cisplatin and Gemcitabine (GC) when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT00942331,NCT00942334,NCT00942334,False,
"Find/search the clinical trial id that best describes the efficacy of FULV compared to Hepatic arterial chemotherapy when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00002716,NCT00259331,NCT00259331,False,
"Find/search the clinical trial id that best describes the efficacy of ddAC-ddT compared to A-T-C when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003088,"Based on the description of the regimens (ddAC-ddT representing dose-dense Adriamycin/Cyclophosphamide followed by dose-dense Taxane, and A-T-C likely representing standard sequential Adriamycin/Cyclophosphamide followed by Taxane, or perhaps concurrent but less likely given the ""dd"" comparison), the clinical trial that most famously compared dose-dense AC-T schedules to standard schedules is CALGB 9741.

The trial id is:
NCT00041119",NCT00041119,False,
"Find/search the clinical trial id that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to Pomalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00833833,NCT01311687,NCT01311687,False,
"Find/search the clinical trial id that best describes the efficacy of Mercaptopurine, Methotrexate, Vincristine compared to Mercaptopurine, Methotrexate, Pegaspargase, Vincristine when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT00075725,NCT00108291,NCT00108291,False,
"Find/search the clinical trial id that best describes the efficacy of Blinatumomab monotherapy compared to Standard salvage consolidation chemotherapy when used to treat B-cell acute lymphoblastic leukemia.
Output it in the format NCT<Number>",NCT02101853,"The clinical trial ID that best describes the efficacy of Blinatumomab monotherapy compared to Standard salvage consolidation chemotherapy when used to treat relapsed/refractory B-cell acute lymphoblastic leukemia is:

NCT01315468",NCT01315468,False,
"Find/search the clinical trial id that best describes the efficacy of COG ANBL0532 Regimen A compared to COG ANBL0532 Regimen B when used to treat Neuroblastoma.
Output it in the format NCT<Number>",NCT00567567,NCT00567721,NCT00567721,False,
"Find/search the clinical trial id that best describes the efficacy of Mercaptopurine, Methotrexate, Vincristine, Dexamethasone compared to Methotrexate and Vincristine when used to treat B-cell acute lymphoblastic leukemia pediatric.
Output it in the format NCT<Number>",NCT00005945,"Based on the specific drug combinations described - Mercaptopurine, Methotrexate, Vincristine, Dexamethasone versus Methotrexate, Vincristine - when used in pediatric B-cell acute lymphoblastic leukemia, the comparison most strongly suggests a question about the components of **maintenance therapy**.

The first regimen (Mercaptopurine, Methotrexate, Vincristine, Dexamethasone) is the standard combination used in the maintenance phase of many successful pediatric ALL protocols (daily oral mercaptopurine, weekly oral methotrexate, and monthly intravenous vincristine and oral dexamethasone pulses). The second regimen (Methotrexate, Vincristine) represents the backbone of this maintenance but omits the crucial daily mercaptopurine and the monthly dexamethasone pulses.

Finding a clinical trial that *directly* randomized patients solely between these two exact regimens as the *only* difference throughout a treatment phase, particularly for efficacy, is challenging. Standard efficacy trials usually compare standard treatment vs. intensification, de-escalation based on response (like MRD), or different durations/schedules. Omitting both mercaptopurine and dexamethasone pulses from maintenance would represent a significant reduction in therapy.

However, major cooperative group trials have investigated reducing the intensity of standard maintenance therapy in specific, usually good-prognosis, subgroups. These trials aim to determine if less chemotherapy (which involves removing or reducing some components of the standard regimen) can maintain efficacy while reducing toxicity.

One such pivotal trial from the Berlin-Frankfurt-Münster (BFM) study group that explored response-guided treatment reduction, including modifications to maintenance therapy components in standard-risk patients, is ALL-BFM 95. While the randomization schema was complex and based on risk, it directly addressed the question of whether a less intensive regimen (derived from the standard multi-agent therapy including the four drugs listed) was sufficient compared to more standard approaches for certain patients. The concept of reducing therapy involved omitting or reducing key components of the standard maintenance, which included the four drugs mentioned.

Although the trial design isn't a simple head-to-head ""4 drugs vs 2 drugs"" comparison across all patients or as the sole difference, the ALL-BFM 95 study (and its subsequent analyses) is highly relevant to the efficacy of regimens including all four drugs compared to less intensive variations missing key components during maintenance in pediatric B-ALL. It represents one of the major efforts to test the necessity of the full complement of standard maintenance drugs in specific patient populations.

Therefore, the clinical trial ID that *best describes* research into the efficacy of regimens like the one including Mercaptopurine, Methotrexate, Vincristine, and Dexamethasone compared to a less intensive regimen omitting key components like Mercaptopurine and Dexamethasone pulses during maintenance in pediatric B-cell ALL, particularly in the context of treatment reduction for good responders, is associated with the ALL-BFM 95 study.

The ClinicalTrials.gov identifier for the ALL-BFM 95 study is NCT00430118.

NCT00430118",NCT00430118,False,
"Find/search the clinical trial id that best describes the efficacy of Best supportive care compared to Docetaxel monotherapy when used to treat Esophageal adenocarcinoma.
Output it in the format NCT<Number>",NCT00978549,"Based on your criteria, the clinical trial that best describes the efficacy of Docetaxel monotherapy compared to Best Supportive Care when used to treat advanced esophago-gastric (which includes esophageal) adenocarcinoma is the COUGAR-02 trial.

The ClinicalTrials.gov identifier for this study is:

NCT00634530",NCT00634530,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Ibrutinib monotherapy when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01973387,"A direct, head-to-head clinical trial comparing Rituximab *monotherapy* to Ibrutinib *monotherapy* for efficacy in Chronic Lymphocytic Leukemia (CLL) is not a common or standard comparison studied in major clinical trials.

Rituximab is typically used in combination with chemotherapy (like FCR or BR) or other targeted agents, rather than as a monotherapy, especially in comparison to highly effective targeted agents like Ibrutinib. Ibrutinib's efficacy as a single agent is significantly higher than Rituximab monotherapy in CLL.

Major trials involving Ibrutinib in CLL usually compare it (either as monotherapy or in combination) against standard chemoimmunotherapy regimens (like FCR or BR). There isn't a prominent clinical trial specifically designed to compare Rituximab *monotherapy* directly against Ibrutinib *monotherapy*.

Therefore, there isn't an NCT number for a trial that *best describes the efficacy of Rituximab monotherapy compared to Ibrutinib monotherapy* because this specific head-to-head monotherapy comparison is not a standard trial design in the current CLL treatment landscape.",,False,
"Find/search the clinical trial id that best describes the efficacy of Capecitabine and Gemcitabine compared to Gemcitabine monotherapy when used to treat Pancreatic cancer.
Output it in the format NCT<Number>",NCT00032175,NCT00064476,NCT00064476,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Nivolumab|Cisplatin, Pemetrexed, Nivolumab when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT02864251,"Based on the comparison of the specified regimens in Non-small cell lung cancer, the clinical trial that best matches this description is:

NCT02574216",NCT02574216,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed|Carboplatin and Paclitaxel .28CP compared to Cisplatin, Pemetrexed, Nivolumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT04025879,"Based on your description of comparing Cisplatin/Carboplatin + Pemetrexed or Carboplatin + Paclitaxel chemotherapy regimens to the same chemotherapy regimens plus Nivolumab for non-squamous non-small cell lung cancer, the clinical trial that best describes this comparison is likely:

NCT02477826",NCT02477826,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Docetaxel (DC) and Nivolumab compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Vinorelbine (CVb)|Cisplatin and Docetaxel (DC) when used to treat Non-small cell lung cancer (Resectable).
Output it in the format NCT<Number>",NCT02998528,"The clinical trial ID that best describes the efficacy of Cisplatin and Docetaxel (DC) and Nivolumab compared to Carboplatin and Paclitaxel (CP), Cisplatin and Vinorelbine (CVb), or Cisplatin and Docetaxel (DC) when used to treat resectable Non-small cell lung cancer is:

NCT04025878",NCT04025878,False,
"Find/search the clinical trial id that best describes the efficacy of Etoposide monotherapy compared to Lenalidomide monotherapy when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT01197560,"Based on searches of clinical trial databases like ClinicalTrials.gov, it appears there is **no registered clinical trial that directly compares Etoposide monotherapy to Lenalidomide monotherapy for efficacy in Diffuse Large B-cell Lymphoma (DLBCL)**.

These two drugs are often used in different contexts or in combination regimens for DLBCL, rather than as directly compared monotherapies in a head-to-head trial for efficacy.

Therefore, an NCT number that precisely describes the comparison you are asking for could not be found.",,False,
"Find/search the clinical trial id that best describes the efficacy of mDCF compared to Cisplatin and Fluorouracil (CF) when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT00811447,"The clinical trial that best describes the efficacy comparison leading to the widespread use of a Docetaxel-containing regimen (like DCF or modified DCF) over Cisplatin and Fluorouracil (CF) in advanced gastric cancer is the **TAX 325 trial**.

While this trial specifically compared the original **DCF** (Docetaxel, Cisplatin, Fluorouracil) to **CF**, its results demonstrating superior survival and response rates for the DCF arm were pivotal. Subsequent modifications (mDCF) aimed to improve the tolerability of the regimen while maintaining similar efficacy to the original DCF. Thus, the TAX 325 trial provides the foundational evidence for the efficacy benefit of adding docetaxel to CF, which applies to the mDCF variation as well compared to CF.

The Clinical Trial ID for the TAX 325 trial is:

NCT00046013",NCT00046013,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Pegylated liposomal doxorubicin compared to Docetaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00091442,NCT00011058,NCT00011058,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00005589,NCT00075984,NCT00075984,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00003204,"Based on a search for clinical trials comparing Rituximab monotherapy to Observation in Chronic Lymphocytic Leukemia, the RiB study is a prominent trial designed to evaluate this specific comparison in early-stage, high-risk patients.

The clinical trial id is:
NCT00943858",NCT00943858,False,
"Find/search the clinical trial id that best describes the efficacy of Dexamethasone monotherapy compared to Thalidomide and Dexamethasone (TD) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00033332,NCT00005900,NCT00005900,False,
"Find/search the clinical trial id that best describes the efficacy of VAD and Valspodar compared to VAD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00002878,NCT00003896,NCT00003896,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Erythropoetin beta and Lenalidomide when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT00843882,"Finding a single clinical trial that *directly* compares Lenalidomide monotherapy head-to-head against Lenalidomide plus Epoetin Beta combination therapy as the primary efficacy comparison in Myelodysplastic Syndrome (MDS) is challenging because this specific comparison isn't a common design for major randomized controlled trials in the field.

Clinical trials involving these drugs in MDS often focus on:
1.  Lenalidomide monotherapy efficacy (especially in del(5q) MDS, compared to placebo or BSC).
2.  Erythropoietin (EPO) efficacy (alone or with G-CSF).
3.  Combinations of agents in specific refractory or higher-risk settings.
4.  Assessing factors influencing Lenalidomide response, which might include prior or concurrent EPO use, but not usually as a primary randomized comparison arm.

Therefore, a specific NCT ID for a trial precisely matching the description of directly comparing Lenalidomide monotherapy vs. Lenalidomide + Epoetin beta combination *within the same trial arms* as the main efficacy question is difficult to identify and likely does not represent a prominent study design in the literature.

As I cannot find a trial that directly and primarily makes this specific comparison, I cannot provide a corresponding NCT number.",,False,
"Find/search the clinical trial id that best describes the efficacy of CHOP compared to R-CHOP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00003150,"NCT00140595

This is the registration number for the pivotal GELA LNH-98-5 trial, which compared R-CHOP to CHOP in elderly patients with diffuse large B-cell lymphoma and demonstrated the superior efficacy of R-CHOP.",NCT00140595,False,
"Find/search the clinical trial id that best describes the efficacy of AT-CMF compared to A-CMF when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003013,"The clinical trial id that best describes the efficacy of AT-CMF compared to A-CMF when used to treat breast cancer is associated with the IBCSG (International Breast Cancer Study Group) Trial 18-98.

NCT00003251",NCT00003251,False,
"Find/search the clinical trial id that best describes the efficacy of Irinotecan monotherapy compared to IROX when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00012389,NCT00115063,NCT00115063,False,
"Find/search the clinical trial id that best describes the efficacy of Prednisone monotherapy compared to Orteronel and Prednisone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT01193244,NCT01193244,NCT01193244,True,
"Find/search the clinical trial id that best describes the efficacy of Tandem melphalan compared to CRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01091831,"Based on a search of clinical trial databases and existing literature, a direct head-to-head randomized clinical trial specifically comparing ""Tandem Melphalan"" (typically referring to tandem autologous stem cell transplant using high-dose melphalan conditioning) against ""CRd"" (Cyclophosphamide, Bortezomib, Dexamethasone) as alternative primary treatment strategies for Multiple Myeloma is not a standard or readily identifiable trial design.

CRd is commonly used as induction therapy *before* a single or tandem transplant, or as a non-transplant regimen. Tandem transplant is a specific type of transplant strategy often compared to single transplant or non-transplant approaches using different novel agent combinations, but not typically directly against CRd as the primary alternative for transplant-eligible patients.

Therefore, there is no known clinical trial ID that specifically and accurately describes the efficacy comparison you've requested.",,False,
"Find/search the clinical trial id that best describes the efficacy of BEP compared to T-BEP when used to treat Testicular cancer.
Output it in the format NCT<Number>",NCT00003643,"NCT00003548

This trial (ECOG-ACRIN Cancer Research Group E3899 / ECOG 0596) is a major Phase III study that compared standard BEP (Bleomycin, Etoposide, Cisplatin) and EP (Etoposide, Cisplatin) regimens with regimens including paclitaxel (leading to T-BEP and TEP variants) in patients with poor-risk germ cell tumors, including advanced testicular cancer. While it included more arms than just BEP vs T-BEP, it is the most significant trial addressing the efficacy of adding paclitaxel to standard BEP-based treatment in this setting.",NCT00003548,False,
"Find/search the clinical trial id that best describes the efficacy of PGC compared to Cisplatin and Gemcitabine (GC) when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT00022191,NCT00003801,NCT00003801,False,
"Find/search the clinical trial id that best describes the efficacy of FULV compared to FOLFIRI when used to treat Colorectal cancer.
Output it in the format NCT<Number>",NCT00004885,NCT00003836,NCT00003836,False,
"Find/search the clinical trial id that best describes the efficacy of MOPP-ABV, then Radiation therapy compared to Radiation therapy when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT00379041,NCT00002547,NCT00002547,False,
"Find/search the clinical trial id that best describes the efficacy of Radiation therapy compared to Observation when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT00005584,"Based on the modern treatment approach for Classical Hodgkin Lymphoma, a direct comparison of *initial* Radiation therapy alone versus Observation alone is not a standard clinical question. Radiation is typically used in conjunction with or after chemotherapy.

However, a major trial that compares Radiation therapy versus Observation *after* initial chemotherapy for early-stage, favorable prognosis Classical Hodgkin Lymphoma patients who achieved a good response is the **RAPID trial**. This trial addressed the question of whether adding radiation after chemotherapy improved outcomes compared to observation alone in this specific population.

The Clinical Trial ID for the RAPID trial is:

NCT00794042",NCT00794042,False,
"Find/search the clinical trial id that best describes the efficacy of ADE (standard-dose Ara-C) compared to ADE (high-dose Ara-C) when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00004128,NCT00431041,NCT00431041,False,
"Find/search the clinical trial id that best describes the efficacy of Camrelizumab monotherapy compared to Irinotecan monotherapy when used to treat Esophageal squamous cell carcinoma.
Output it in the format NCT<Number>",NCT03099382,NCT02564493,NCT02564493,False,
"Find/search the clinical trial id that best describes the efficacy of Erlotinib monotherapy compared to Cisplatin and Docetaxel (DC) when used to treat Non-small cell lung cancer (Metastatic).
Output it in the format NCT<Number>",NCT00446225,"Based on a search of clinical trial databases, the trial that best fits the description of comparing Erlotinib monotherapy to Cisplatin and Docetaxel combination therapy for metastatic non-small cell lung cancer is:

NCT00003229",NCT00003229,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Cisplatin and Fluorouracil (CF), then Gemcitabine monotherapy when used to treat Pancreatic cancer.
Output it in the format NCT<Number>",NCT00416507,"The clinical trial that best describes the efficacy of Gemcitabine monotherapy and is often cited as the pivotal study establishing it as a standard for advanced pancreatic cancer, compared to the then-standard 5-Fluorouracil (related to the ""CF"" context as 5-FU was a component of common regimens), is:

NCT00003204",NCT00003204,False,
"Find/search the clinical trial id that best describes the efficacy of Cyclosporine and Mycophenolate mofetil compared to Cyclosporine, Mycophenolate mofetil, Sirolimus when used to treat Graft versus host disease.
Output it in the format NCT<Number>",NCT01231412,NCT00004662,NCT00004662,False,
"Find/search the clinical trial id that best describes the efficacy of Fludarabine and TBI compared to Low-dose TBI when used to treat Allogeneic HSCT.
Output it in the format NCT<Number>",NCT00075478,"Based on a search of clinical trial databases, finding a trial that *directly* compares Fludarabine combined with TBI against *only* Low-dose TBI as the conditioning regimen for Allogeneic HSCT efficacy is difficult.

Most comparative trials in this context compare:
1.  Fludarabine/Low-dose TBI (as a reduced-intensity regimen) against a different reduced-intensity regimen (e.g., Fludarabine/Busulfan, Fludarabine/Melphalan).
2.  A reduced-intensity regimen (often including Fludarabine and/or low-dose TBI) against a myeloablative regimen (like high-dose TBI or Busulfan/Cyclophosphamide).

A regimen consisting solely of low-dose TBI is not a standard comparator arm against a combined Fludarabine/TBI regimen for head-to-head efficacy comparison in typical trials.

Therefore, there isn't a single, well-known NCT trial ID that precisely fits the description of comparing *Fludarabine+TBI* vs. *Low-dose TBI alone* for efficacy in Allogeneic HSCT.",,False,
"Find/search the clinical trial id that best describes the efficacy of PCDE compared to Cisplatin and Etoposide (EP) when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00003606,"It appears the acronym ""PCDE"" is not a standard, widely recognized chemotherapy regimen for Small Cell Lung Cancer (SCLC). Common regimens involve combinations of Platinum (Cisplatin or Carboplatin) and Etoposide (EP or CE), or combinations like Cyclophosphamide, Doxorubicin, and Vincristine (CAV), or sometimes regimens like Cyclophosphamide, Doxorubicin, and Etoposide (CDE).

It is possible that ""PCDE"" is a typo, a less common local acronym, or refers to a specific, potentially experimental regimen.

However, there have been clinical trials comparing regimens based on the components you listed. A prominent trial compared Cyclophosphamide, Doxorubicin, and Etoposide (CDE) to Carboplatin and Etoposide (CE), which is a common alternative to Cisplatin and Etoposide (EP). This trial directly compares a CDE-based regimen to an EP-like regimen (CE).

Based on the likely intent behind your query (comparing a CDE-like regimen to an EP-like regimen), the clinical trial id that best describes this comparison for extensive stage SCLC is:

NCT00003735

This trial compared Carboplatin/Etoposide (CE) to Cyclophosphamide/Doxorubicin/Etoposide (CDE).",NCT00003735,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Carfilzomib and Lenalidomide (KR) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT02203643,"Based on the search criteria, the clinical trial that best describes the efficacy comparison of Lenalidomide monotherapy to Carfilzomib and Lenalidomide (KR) in Multiple Myeloma is:

NCT01937554

This was a Phase 1b/2 randomized study specifically designed with arms comparing Lenalidomide monotherapy and the combination of Carfilzomib and Lenalidomide in patients with relapsed and/or refractory multiple myeloma. While primarily focused on safety and dose, efficacy was evaluated as a secondary outcome.",NCT01937554,False,
"Find/search the clinical trial id that best describes the efficacy of Venetoclax and Obinutuzumab compared to Bendamustine and Rituximab (BR) when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT02950051,NCT02242942,NCT02242942,False,
"Find/search the clinical trial id that best describes the efficacy of Dexamethasone monotherapy compared to Thalidomide and Dexamethasone (TD) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01296503,"Based on your criteria, the clinical trial ID that best describes the efficacy comparison of Dexamethasone monotherapy to Thalidomide and Dexamethasone (TD) for Multiple Myeloma, often considered a foundational trial in establishing the use of TD, is:

NCT00034558",NCT00034558,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Lenalidomide monotherapy when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01556776,NCT00917540,NCT00917540,False,
"Find/search the clinical trial id that best describes the efficacy of FAC compared to FAC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129389,"Based on your description, the clinical trial ID that best describes the efficacy comparison of FAC vs. FAC-T (specifically T-FAC, where T is Docetaxel) for treating breast cancer is:

NCT00002882",NCT00002882,False,
"Find/search the clinical trial id that best describes the efficacy of ET-X compared to EC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129935,"Based on the interventions ET-X (likely Epirubicin + Taxane + Capecitabine) and EC-D (Epirubicin + Cyclophosphamide + Docetaxel) in the context of breast cancer, a prominent clinical trial comparing regimens fitting this description is the GEICAM/2003-02 study.

The clinical trial id that best describes a comparison of regimens similar to ET-X (Epirubicin/Docetaxel followed by Capecitabine) versus EC-D (Epirubicin/Cyclophosphamide followed by Docetaxel) for treating breast cancer is:

NCT00129921",NCT00129921,False,
"Find/search the clinical trial id that best describes the efficacy of EC-TH (Docetaxel) compared to EC-TL (Docetaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00841828,"Based on the search for clinical trials comparing regimens with a similar structure (Epirubicin, Cyclophosphamide, Docetaxel - EC-T) combined with either Trastuzumab (H) or Lapatinib (L) for breast cancer, the most relevant large-scale trial comparing Trastuzumab vs Lapatinib on a very similar chemotherapy backbone is:

NCT00390409",NCT00390409,False,
"Find/search the clinical trial id that best describes the efficacy of TAC (Docetaxel) compared to FAC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00121992,NCT00050220,NCT00050220,False,
"Find/search the clinical trial id that best describes the efficacy of FEC-P compared to FEC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00129922,"Based on a search of clinical trial databases and literature, the term ""FEC-P"" typically refers to a regimen involving Fluorouracil, Epirubicin, Cyclophosphamide (FEC) plus Paclitaxel. This is most commonly administered sequentially (FEC followed by Paclitaxel) rather than concurrently as a four-drug combination.

A major clinical trial that evaluated the efficacy of adding a taxane sequence after FEC compared to FEC alone in early breast cancer is the **PACS 01** trial. This trial compared 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of Docetaxel. While it used Docetaxel instead of Paclitaxel, it is a landmark study demonstrating the benefit of adding a taxane sequentially to an FEC backbone and directly addresses the efficacy question you raised regarding adding a taxane (like Paclitaxel or Docetaxel) to FEC.

The ClinicalTrials.gov identifier for the PACS 01 trial is:

NCT00004203",NCT00004203,False,
"Find/search the clinical trial id that best describes the efficacy of Ibrutinib monotherapy compared to Ibrutinib and Ublituximab when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT02301156,NCT02301156,NCT02301156,True,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Erythropoetin beta and Lenalidomide when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01718379,NCT00667258,NCT00667258,False,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Dactinomycin monotherapy when used to treat Gestational trophoblastic neoplasia.
Output it in the format NCT<Number>",NCT00003702,NCT00003972,NCT00003972,False,
"Find/search the clinical trial id that best describes the efficacy of Ifosfamide and Paclitaxel compared to Ifosfamide monotherapy when used to treat Endometrial cancer.
Output it in the format NCT<Number>",NCT00003128,"Based on the description of comparing Ifosfamide and Paclitaxel combination therapy to Ifosfamide monotherapy for Endometrial cancer, the clinical trial ID is:

NCT00003623",NCT00003623,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin, Doxorubicin, Paclitaxel compared to Cisplatin and Doxorubicin when used to treat Endometrial cancer.
Output it in the format NCT<Number>",NCT00003691,NCT00002884,NCT00002884,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Paclitaxel compared to Cisplatin and Gemcitabine (GC) when used to treat Cervical cancer.
Output it in the format NCT<Number>",NCT00064077,"Based on searching for clinical trials comparing Cisplatin/Paclitaxel against Cisplatin/Gemcitabine specifically for cervical cancer, the most relevant and significant trial that included both of these regimens (among others) is the GOG-204 study.

The Clinical Trial ID for this study is:

NCT00046932",NCT00046932,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel monotherapy compared to Olaparib and Paclitaxel when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT01924533,NCT01924533,NCT01924533,True,
"Find/search the clinical trial id that best describes the efficacy of ABVD compared to eBEACOPP-BEACOPP when used to treat Classical Hodgkin lymphoma.
Output it in the format NCT<Number>",NCT01251107,"The pivotal clinical trial that directly compared ABVD to escalated BEACOPP (eBEACOPP) in patients with advanced Classical Hodgkin Lymphoma and established the superior efficacy of eBEACOPP (though with increased toxicity) was the **GHSG HD9 trial**.

However, the original GHSG HD9 trial was conducted before mandatory widespread registration of clinical trials, and it does not appear to have a standard, easily searchable NCT number associated with the primary publication (Engert et al., NEJM 2002).

The subsequent major trial by the same group, building directly on the findings of HD9 and focusing on optimizing the eBEACOPP regimen, is **GHSG HD15**. This trial compared different numbers of cycles of eBEACOPP, operating under the premise established by HD9 regarding eBEACOPP's efficacy compared to ABVD. This trial *is* registered and its registration information references the context of HD9.

Therefore, while GHSG HD9 performed the initial key comparison, the most relevant *registered* clinical trial identifier relating to the established efficacy of BEACOPP vs. ABVD, as it built directly upon those findings, is for GHSG HD15.

NCT00265011",NCT00265011,False,
"Find/search the clinical trial id that best describes the efficacy of EC-D and Bevacizumab compared to EC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00567554,"The clinical trial that best describes the efficacy comparison of EC-D and Bevacizumab versus EC-D alone for treating breast cancer is likely the **RIBBON-1** trial. This large Phase III trial evaluated Bevacizumab plus chemotherapy versus chemotherapy alone in patients with previously untreated HER2-negative metastatic breast cancer, and one of the allowed chemotherapy backbones was an anthracycline/taxane combination like EC-D.

The ClinicalTrials.gov identifier for the RIBBON-1 trial is:

NCT00090124",NCT00090124,False,
"Find/search the clinical trial id that best describes the efficacy of Letrozole and OFS compared to Tamoxifen and OFS when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00412022,"The clinical trial that best describes the efficacy of an aromatase inhibitor (specifically Exemestane, which is similar to Letrozole in this context) and Ovarian Function Suppression (OFS) compared to Tamoxifen and OFS in treating breast cancer is the TEXT trial.

NCT00066703",NCT00066703,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Epirubicin compared to E-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00424606,"Based on the description of comparing regimens containing Docetaxel and Epirubicin for efficacy in breast cancer, specifically against an ""E-D"" (Epirubicin-Docetaxel) combination, a highly relevant Phase 3 trial that compared different *regimens* containing Epirubicin and Docetaxel (along with Cyclophosphamide, which is common) is the GEICAM 9906 study.

This trial compared six cycles of **EC-T** (Epirubicin and Cyclophosphamide followed sequentially by Docetaxel) versus six cycles of **ETC** (Concurrent Epirubicin, Docetaxel, and Cyclophosphamide) as adjuvant therapy for node-positive breast cancer. While not a direct comparison of *just* ED vs. something else, it directly addresses the efficacy of different ways of combining key drugs including Epirubicin and Docetaxel.

The ClinicalTrials.gov identifier for the GEICAM 9906 trial is:

NCT00129924",NCT00129924,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Vinorelbine monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00441922,NCT00003579,NCT00003579,False,
"Find/search the clinical trial id that best describes the efficacy of R-DHAP/R-VIM compared to DHAP/VIM when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00012051,"The clinical trial that best describes the comparison of R-DHAP/R-VIM to DHAP/VIM for relapsed/refractory Diffuse large B-cell lymphoma, demonstrating the superiority of adding Rituximab, is often cited as a key study supporting the use of R-containing salvage regimens which superseded non-R regimens. While there might not be a single large Phase 3 trial *explicitly* randomizing R-DHAP vs. DHAP *alone* (as the benefit of Rituximab became clear earlier), the CORAL trial is a landmark study in this setting involving R-DHAP that provides evidence for R-containing salvage therapies.

The trial is:
NCT00078921",NCT00078921,False,
"Find/search the clinical trial id that best describes the efficacy of Busulfan and Melphalan compared to Carboplatin, Etoposide, Melphalan, then auto HSCT when used to treat Neuroblastoma.
Output it in the format NCT<Number>",NCT01704716,NCT00003118,NCT00003118,False,
"Find/search the clinical trial id that best describes the efficacy of Melphalan monotherapy compared to Melphalan and Dexamethasone when used to treat Light-chain (AL) amyloidosis.
Output it in the format NCT<Number>",NCT00344526,NCT00055212,NCT00055212,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin monotherapy compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT00002894,"Based on your criteria (Carboplatin monotherapy compared to Carboplatin and Paclitaxel | Cisplatin and Paclitaxel for Ovarian cancer efficacy), the trial that directly compares Carboplatin alone versus Carboplatin/Paclitaxel combination therapy is a strong candidate.

A key trial addressing this specific comparison is:

NCT00002603",NCT00002603,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00430365,"Based on searching major clinical trial databases for studies comparing Lenalidomide monotherapy to Placebo in Multiple Myeloma, a prominent and well-cited trial that fits this description, particularly in the maintenance setting, is:

NCT00096587",NCT00096587,False,
"Find/search the clinical trial id that best describes the efficacy of VDC compared to VTD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01971658,NCT01203184,NCT01203184,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pemetrexed, Atezolizumab compared to Carboplatin and Pemetrexed|Cisplatin and Pemetrexed when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02657434,NCT02657434,NCT02657434,True,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Pemetrexed monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01836575,"Based on your description, the clinical trial that best fits the comparison of Carboplatin and Pemetrexed combination therapy versus Pemetrexed monotherapy for efficacy in Non-small cell lung cancer (specifically in previously treated patients, which is a common setting for this comparison) is:

NCT00110763",NCT00110763,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00478049,"The clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Gefitinib monotherapy when used to treat previously treated advanced non-small cell lung cancer is:

NCT00071841",NCT00071841,False,
"Find/search the clinical trial id that best describes the efficacy of Prednisone monotherapy compared to Dexamethasone monotherapy when used to treat Immune thrombocytopenia.
Output it in the format NCT<Number>",NCT01356511,NCT00441745,NCT00441745,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Urothelial carcinoma.
Output it in the format NCT<Number>",NCT01282463,NCT02330667,NCT02330667,False,
"Find/search the clinical trial id that best describes the efficacy of Pemetrexed monotherapy compared to Best supportive care when used to treat Malignant pleural mesothelioma.
Output it in the format NCT<Number>",NCT00190762,"Based on the historical clinical trials for Pemetrexed in Malignant Pleural Mesothelioma, the key trial that established the efficacy of Pemetrexed, demonstrating outcomes superior to Best Supportive Care, was a Phase II study investigating Pemetrexed monotherapy. While the later pivotal Phase III trial (MP001) compared Pemetrexed + Cisplatin vs. Cisplatin, the activity of Pemetrexed *monotherapy* vs. BSC was primarily supported by earlier data.

The clinical trial ID that best describes the investigation of Pemetrexed monotherapy's efficacy in this context is:

NCT00003233",NCT00003233,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Etoposide (CE) compared to Carboplatin and Pemetrexed when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00363415,NCT01445087,NCT01445087,False,
"Find/search the clinical trial id that best describes the efficacy of Gefitinib and Pemetrexed compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01469000,"Based on a search of clinical trial databases for studies comparing Gefitinib and Pemetrexed combination therapy to Gefitinib monotherapy for the treatment of Non-Small Cell Lung Cancer focusing on efficacy, the following trial is a relevant match:

NCT01244172",NCT01244172,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Pembrolizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02039674,NCT02578680,NCT02578680,False,
"Find/search the clinical trial id that best describes the efficacy of Pembrolizumab monotherapy compared to Carboplatin and Paclitaxel (CP)|Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03850444,"NCT02142785

This is the trial identifier for KEYNOTE-024, which compared Pembrolizumab monotherapy to platinum-based chemotherapy (including Carboplatin/Paclitaxel and Carboplatin/Pemetrexed based on histology) in previously untreated advanced NSCLC patients with high PD-L1 expression (TPS >= 50%).",NCT02142785,False,
"Find/search the clinical trial id that best describes the efficacy of Pembrolizumab monotherapy compared to Paclitaxel monotherapy when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT03019588,"The clinical trial ID that best describes the efficacy of Pembrolizumab monotherapy compared to Paclitaxel monotherapy when used to treat Gastric cancer is:

NCT02370491

This is the ID for the KEYNOTE-061 study, a Phase 3 trial comparing Pembrolizumab monotherapy to Paclitaxel monotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma that progressed after first-line chemotherapy.",NCT02370491,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, nab-Paclitaxel, Pembrolizumab compared to Carboplatin and Paclitaxel (CP)|Carboplatin and nab-Paclitaxel when used to treat Non-small cell lung cancer squamous.
Output it in the format NCT<Number>",NCT03875092,"Based on your description of the interventions (Carboplatin + nab-Paclitaxel + Pembrolizumab compared to Carboplatin + Paclitaxel or Carboplatin + nab-Paclitaxel) and the disease (Non-small cell lung cancer squamous), the clinical trial that best fits is the KEYNOTE-407 study.

NCT02519342",NCT02519342,False,
"Find/search the clinical trial id that best describes the efficacy of Capecitabine and Cisplatin (CX) compared to Capecitabine and Cisplatin (CX) and Pembrolizumab|Cisplatin and Fluorouracil (CF) and Pembrolizumab when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT03221426,"Based on the description, the clinical trial that best describes the efficacy of Pembrolizumab in combination with standard chemotherapy regimens (which included Capecitabine and Cisplatin or Fluorouracil and Cisplatin options) compared to chemotherapy alone in treating gastric cancer is:

NCT02493751",NCT02493751,False,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin and Pemetrexed compared to Cisplatin, Pemetrexed, Pembrolizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03425643,"NCT02578680

This NCT ID corresponds to the KEYNOTE-189 trial, which was a large Phase 3 study comparing Pembrolizumab plus Platinum-Pemetrexed chemotherapy versus placebo plus Platinum-Pemetrexed chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung cancer.",NCT02578680,False,
"Find/search the clinical trial id that best describes the efficacy of Dara-Vd compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03234972,"NCT02136134

This is the NCT number for the CASTOR study, a pivotal Phase 3 trial comparing Daratumumab in combination with Bortezomib and Dexamethasone (Dara-Vd) versus Bortezomib and Dexamethasone (Vd) alone in patients with relapsed or refractory multiple myeloma.",NCT02136134,False,
"Find/search the clinical trial id that best describes the efficacy of Ipatasertib and Paclitaxel compared to Paclitaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT02162719,NCT03037385,NCT03037385,False,
"Find/search the clinical trial id that best describes the efficacy of Nintedanib and Pemetrexed compared to Pemetrexed monotherapy when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT00806819,"The clinical trial id that best describes the efficacy of Nintedanib and Pemetrexed compared to Pemetrexed-based chemotherapy (followed by maintenance) in patients with advanced non-squamous NSCLC, which is the basis for the use of Nintedanib in this setting, is:

NCT00810980",NCT00810980,False,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Afatinib monotherapy when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01345682,"Based on a search of clinical trial databases for a head-to-head comparison of Afatinib monotherapy vs. Methotrexate monotherapy for Head and Neck Cancer efficacy, the key trial is:

NCT01345669",NCT01345669,False,
"Find/search the clinical trial id that best describes the efficacy of Methotrexate monotherapy compared to Afatinib monotherapy when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT01856478,NCT02395327,NCT02395327,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Pemetrexed compared to Carboplatin, Pemetrexed, Amivantamab when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT04988295,NCT04538664,NCT04538664,False,
"Find/search the clinical trial id that best describes the efficacy of Azacitidine monotherapy compared to Decitabine monotherapy when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01720225,"Based on a search of clinical trial databases for trials directly comparing Azacitidine monotherapy to Decitabine monotherapy for the treatment of Myelodysplastic Syndromes and focusing on efficacy:

NCT01027823",NCT01027823,False,
"Find/search the clinical trial id that best describes the efficacy of R-Hyper-CVAD/R-MA compared to R-CHOP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00290498,NCT00064260,NCT00064260,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Myelodysplastic syndrome.
Output it in the format NCT<Number>",NCT01029262,NCT00102644,NCT00102644,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab|Carboplatin and Gemcitabine (GCb) and Bevacizumab|Carboplatin and Paclitaxel (CP) and Bevacizumab compared to Carboplatin and Gemcitabine (GCb) when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT01802749,"Based on your description of the drug combinations and the comparison to Carboplatin and Gemcitabine (GCb) in Ovarian Cancer, the clinical trial that best fits involves testing Bevacizumab added to standard platinum-based doublets (like GCb or Carboplatin/Pegylated Liposomal Doxorubicin) in recurrent disease.

The trial that most closely matches this description, particularly involving Carboplatin, Gemcitabine, Pegylated liposomal doxorubicin, and Bevacizumab, and comparing Bevacizumab combinations against chemotherapy alone (including GCb as a control arm), is the AGO-OVAR 2.21 trial.

The ClinicalTrials.gov identifier for this trial is:

NCT01121313",NCT01121313,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00405756,"The clinical trial that perhaps best describes the efficacy of Lenalidomide monotherapy compared to Placebo in Multiple Myeloma, specifically in the maintenance setting after stem cell transplant, is:

NCT00114931",NCT00114931,False,
"Find/search the clinical trial id that best describes the efficacy of Thalidomide and Dexamethasone (TD) compared to VTD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00256776,NCT00268268,NCT00268268,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Lenalidomide monotherapy when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00551928,"The clinical trial id that best describes the efficacy of Lenalidomide monotherapy compared to Observation in Multiple Myeloma (specifically high-risk smoldering multiple myeloma, which is a common setting for this comparison) is:

NCT01169337",NCT01169337,False,
"Find/search the clinical trial id that best describes the efficacy of FLA compared to ADE (standard-dose Ara-C) when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00005863,"Based on the search criteria, a significant clinical trial comparing a Fludarabine-containing regimen (FLAG-IDA) to a standard induction regimen (7+3, which uses standard-dose Cytarabine/Ara-C and an anthracycline) for untreated AML is a strong candidate.

The trial id is:
NCT00490928",NCT00490928,False,
"Find/search the clinical trial id that best describes the efficacy of ICE-V compared to CDE when used to treat Small cell lung cancer.
Output it in the format NCT<Number>",NCT00002822,NCT00003794,NCT00003794,False,
"Find/search the clinical trial id that best describes the efficacy of ABCM compared to Melphalan and Methylprednisolone when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00002599,"Based on the drugs in question (Adriamycin/Doxorubicin (A), Carmustine/BCNU (B), Cyclophosphamide (C), Melphalan (M) - ABCM) compared to Melphalan (M) and Methylprednisolone/Prednisone (P - MP), this likely refers to clinical trials comparing intensive chemotherapy regimens (often including components of ABCM, sometimes as conditioning for transplant) against conventional Melphalan and Prednisolone (MP) in Multiple Myeloma.

A key and often-cited trial in this area that compared an intensive strategy (involving drugs related to ABCM) against a conventional MP-based strategy is the IFM 90 trial. While the intensive arm specifically used VAD induction followed by high-dose Melphalan and autologous stem cell transplant, and the conventional arm used VAD followed by MP, it represents a major comparison of intensive therapy (including Doxorubicin and Melphalan) versus conventional MP therapy for multiple myeloma, fitting the spirit of your request for an efficacy comparison between these types of regimens.

The clinical trial id for the IFM 90 study is:

NCT00002527",NCT00002527,False,
"Find/search the clinical trial id that best describes the efficacy of mFOLFOX6 and Cetuximab compared to mFOLFOX6 when used to treat Colon cancer.
Output it in the format NCT<Number>",NCT00079274,"Based on your request, the clinical trial id that best describes the efficacy of mFOLFOX6 and Cetuximab compared to mFOLFOX6 when used to treat Colon cancer is likely a large, phase III study directly comparing these regimens.

One such trial that fits this description is:

NCT00265821",NCT00265821,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP) and Nivolumab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT03838159,"Based on your description, the clinical trial that best fits this comparison, specifically looking at adding a Nivolumab-based regimen to chemotherapy versus chemotherapy alone (which included Carboplatin and Paclitaxel for many patients in the control arm), is:

**CheckMate 9LA**

The ClinicalTrials.gov identifier for this study is:

NCT03164616

This trial evaluated Nivolumab plus Ipilimumab plus 2 cycles of chemotherapy (like CP) compared to 4 cycles of chemotherapy alone (like CP) for the first-line treatment of advanced NSCLC. It demonstrated improved overall survival and progression-free survival in the immunotherapy plus chemotherapy arm compared to chemotherapy alone.",NCT03164616,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine and Vinorelbine compared to Cisplatin and Vinorelbine (CVb) when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00004100,"Based on a search of clinical trial databases focusing on direct comparisons of these regimens in NSCLC, a relevant Phase III trial that included this comparison is:

NCT00102687",NCT00102687,False,
"Find/search the clinical trial id that best describes the efficacy of Tamoxifen monotherapy compared to Placebo when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002542,"Searching ClinicalTrials.gov for studies comparing Tamoxifen monotherapy to Placebo for the treatment of breast cancer (specifically focusing on efficacy) often points towards trials conducted in the metastatic or advanced setting, as direct placebo comparisons for early-stage curative treatment are less common in modern trials due to ethical considerations and established standard care.

One relevant completed Phase III trial is:

**NCT00003984**

This trial investigated Tamoxifen vs. Placebo in patients with metastatic breast cancer who had progressed on a prior first-line endocrine therapy. While it's a second-line setting, it directly compares Tamoxifen monotherapy efficacy against a placebo control in established, actively treated breast cancer.

Therefore, a strong candidate for the clinical trial ID that best describes the efficacy of Tamoxifen monotherapy compared to Placebo when used to treat Breast cancer (particularly advanced disease) is:

NCT00003984",NCT00003984,False,
"Find/search the clinical trial id that best describes the efficacy of ddEC-T compared to AC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00014222,"Based on the available clinical trial data and common chemotherapy regimens for breast cancer, a large, phase 3 randomized clinical trial *specifically* comparing **dose-dense Epirubicin/Cyclophosphamide followed by Paclitaxel (ddEC-T)** head-to-head against **standard-dose Doxorubicin/Cyclophosphamide followed by Paclitaxel (AC-T)** as its *primary* objective is not a widely recognized landmark study.

However, trials comparing **dose-dense** regimens to **standard-dose** regimens in this class (anthracycline/cyclophosphamide followed by taxane) are highly relevant. The most famous and impactful trial demonstrating the efficacy benefit of a dose-dense approach compared to standard AC-T is the CALGB 9741 study. While it specifically compared dose-dense AC-T (ddAC-T) to standard AC-T, it established the principle of dose-dense scheduling efficacy that is applicable to similar regimens like ddEC-T.

Considering ""best describes the efficacy... compared to AC-T"", the trial that directly used **AC-T as the standard comparator** and showed a significant efficacy difference with a dose-dense regimen of this type is:

**NCT00003820**",NCT00003820,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Lapatinib (TL)|Lapatinib and Paclitaxel compared to Paclitaxel and Trastuzumab (TH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00667251,"Based on the drug combinations and the comparison described (Lapatinib/chemo vs Trastuzumab/chemo), the clinical trial that best fits this description is the **COMPARZ** trial, which compared Lapatinib plus paclitaxel (LP) or capecitabine (LC) to Trastuzumab plus paclitaxel (TH) or capecitabine (XH) in patients with HER2-positive metastatic breast cancer.

The trial ID is:
NCT00876557",NCT00876557,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Erlotinib and Gemcitabine when used to treat Pancreatic cancer (Locally Advanced or Unresectable or Metastatic).
Output it in the format NCT<Number>",NCT00026338,NCT00042925,NCT00042925,False,
"Find/search the clinical trial id that best describes the efficacy of ADT compared to ADT and RT when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00002633,NCT00002607,NCT00002607,False,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to Observation when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002582,"Based on searching for trials comparing CMF to Observation in breast cancer and focusing on those with an NCT number, one significant trial is:

NCT00003636",NCT00003636,False,
"Find/search the clinical trial id that best describes the efficacy of CHOP (Prednisolone) compared to BCHOP when used to treat Mantle cell lymphoma.
Output it in the format NCT<Number>",NCT00513955,NCT00640320,NCT00640320,False,
"Find/search the clinical trial id that best describes the efficacy of ATG (Horse) and Cyclosporine compared to ATG (Rabbit) and Cyclosporine when used to treat Aplastic anemia.
Output it in the format NCT<Number>",NCT00260689,"The clinical trial id that best describes a direct comparison of the efficacy of Horse ATG and Cyclosporine versus Rabbit ATG and Cyclosporine for treating Aplastic Anemia, particularly Severe Aplastic Anemia, is:

NCT00643032",NCT00643032,False,
"Find/search the clinical trial id that best describes the efficacy of No induction compared to Bortezomib and Dexamethasone (Vd) when used to treat Light-chain (AL) amyloidosis.
Output it in the format NCT<Number>",NCT01998503,"Based on searches of clinical trial databases (like ClinicalTrials.gov), a large, randomized controlled trial *directly* comparing Bortezomib and Dexamethasone (Vd) to *no systemic induction therapy* for treating Light-chain (AL) amyloidosis is unlikely to exist.

AL amyloidosis is a serious condition requiring active treatment for organ preservation and improved survival. ""No induction"" (meaning no systemic treatment) is generally not an ethical or effective control arm for newly diagnosed patients requiring therapy, as untreated disease has a poor prognosis.

The efficacy of Vd (or bortezomib-based regimens like VCd - Bortezomib, Cyclophosphamide, Dexamethasone) was primarily established in trials comparing it to previous standard treatments, such as Melphalan and Dexamethasone (Md), or other combination regimens.

Therefore, there is no specific clinical trial ID (NCT number) that represents a direct comparison of Vd vs. ""No induction"" therapy for treating AL amyloidosis.",,False,
"Find/search the clinical trial id that best describes the efficacy of Bortezomib monotherapy compared to Observation when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00417911,"Based on your criteria, the clinical trial that best describes a randomized comparison of Bortezomib monotherapy versus Observation for efficacy in the Multiple Myeloma disease spectrum (specifically high-risk smoldering multiple myeloma aimed at delaying progression to active MM) is:

NCT01301959",NCT01301959,False,
"Find/search the clinical trial id that best describes the efficacy of TAC (Docetaxel) compared to AC-D when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003782,NCT00124500,NCT00124500,False,
"Find/search the clinical trial id that best describes the efficacy of AC-TH (Paclitaxel) compared to AC-THL (Paclitaxel) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00486668,"Based on a search of clinical trial databases for studies comparing the AC-TH (Doxorubicin + Cyclophosphamide followed by Paclitaxel + Trastuzumab) regimen versus the AC-THL (AC followed by Paclitaxel + Trastuzumab + Lapatinib) regimen for breast cancer, the following trial directly compares these two regimens in an adjuvant setting:

NCT00648783",NCT00648783,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Erlotinib compared to Docetaxel monotherapy when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT02775006,"Based on your criteria (efficacy of Docetaxel and Erlotinib combination compared to Docetaxel monotherapy in NSCLC), the clinical trial ID that best matches this specific comparison is:

NCT01203917",NCT01203917,False,
"Find/search the clinical trial id that best describes the efficacy of EC-ddT compared to ddT-EC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00070278,"The clinical trial id that best describes the efficacy comparison of sequential Epirubicin/Cyclophosphamide followed by Docetaxel (EC-dT) versus Docetaxel followed by Epirubicin/Cyclophosphamide (dT-EC) in breast cancer is likely:

NCT00057897",NCT00057897,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Sintilimab monotherapy when used to treat Non-small cell lung cancer squamous.
Output it in the format NCT<Number>",NCT03150875,NCT03521164,NCT03521164,False,
"Find/search the clinical trial id that best describes the efficacy of Rituximab monotherapy compared to Observation when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00718549,NCT00059143,NCT00059143,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin, Pemetrexed, Amivantamab compared to Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic).
Output it in the format NCT<Number>",NCT04538664,NCT04538664,NCT04538664,True,
"Find/search the clinical trial id that best describes the efficacy of RVD compared to Dara-RVd (SC daratumumab) when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT03710603,NCT03710603,NCT03710603,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH) and Pyrotinib compared to Docetaxel and Trastuzumab (TH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT03588091,NCT03080580,NCT03080580,False,
"Find/search the clinical trial id that best describes the efficacy of Gemcitabine monotherapy compared to Adavosertib and Gemcitabine when used to treat Ovarian cancer.
Output it in the format NCT<Number>",NCT02101775,NCT02163697,NCT02163697,False,
"Find/search the clinical trial id that best describes the efficacy of Pomalidomide and Dexamethasone (Pd) compared to PCD when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01432600,NCT01734080,NCT01734080,False,
"Find/search the clinical trial id that best describes the efficacy of R-CHOP compared to Pola-R-CHP when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT03274492,"The clinical trial ID that best describes the efficacy of R-CHOP compared to Pola-R-CHP when used to treat Diffuse large B-cell lymphoma is:

NCT03274492",NCT03274492,True,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel, Enzalutamide, Prednisolone compared to Docetaxel and Prednisolone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT02288247,"Based on your description, the clinical trial that best matches the comparison of Docetaxel, Enzalutamide, Prednisolone against Docetaxel and Prednisolone for the treatment of Prostate Cancer is likely:

NCT00268476",NCT00268476,False,
"Find/search the clinical trial id that best describes the efficacy of ADT compared to ADT, Abiraterone, Apalutamide when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT03009981,"Based on your request for a clinical trial comparing ADT to ADT, Abiraterone, and Apalutamide for prostate cancer efficacy, it's important to note that there isn't one single clinical trial that directly compares ADT alone vs. ADT + Abiraterone vs. ADT + Apalutamide in *all three arms simultaneously*.

However, large Phase 3 trials have established the efficacy of ADT + Abiraterone and ADT + Apalutamide compared to ADT alone in specific prostate cancer settings (like metastatic hormone-sensitive prostate cancer). Two of the key trials are:

1.  **LATITUDE:** Compared ADT + Abiraterone vs. ADT + Placebo in high-risk metastatic hormone-sensitive prostate cancer.
2.  **TITAN:** Compared ADT + Apalutamide vs. ADT + Placebo in metastatic hormone-sensitive prostate cancer.
3.  **STAMPEDE:** A multi-arm platform trial that included arms comparing ADT alone vs. ADT + Abiraterone (among others) in hormone-sensitive prostate cancer.

The **STAMPEDE** trial is a particularly relevant multi-arm trial that directly compared ADT alone to ADT + Abiraterone within its framework (among other comparisons), providing strong evidence for the benefit of intensifying ADT. While it didn't include an Apalutamide arm, it serves as a significant trial showing the benefit of combination therapy over ADT alone.

Considering your request implies a comparison involving ADT alone against combinations, STAMPEDE (with its ADT alone control arm and ADT + Abiraterone arm) is a highly relevant trial ID.

The clinical trial ID for the STAMPEDE trial is:

NCT00268476",NCT00268476,False,
"Find/search the clinical trial id that best describes the efficacy of Crizotinib monotherapy compared to Carboplatin and Pemetrexed when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01639001,"Based on your description, the clinical trial that best fits is the PROFILE 1014 study, which compared Crizotinib to chemotherapy (Pemetrexed plus Carboplatin or Cisplatin) in previously untreated ALK-positive NSCLC.

The ClinicalTrials.gov identifier for this study is:
NCT01154474",NCT01154474,False,
"Find/search the clinical trial id that best describes the efficacy of CHUT compared to Observation when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002870,"I cannot find any standard clinical trial listed under the acronym ""CHUT"" for breast cancer treatment.

""CHUT"" is not a recognized or standard acronym for a specific breast cancer therapy, drug, or regimen in clinical trial databases.

Clinical trials are typically indexed using established names for drugs, procedures, or treatment types (like Chemotherapy, Hormonal Therapy, Radiation Therapy, targeted drug names, etc.). It's highly unlikely a trial would be listed solely under the acronym ""CHUT"".

Could you please confirm the correct name or acronym for the treatment you are referring to? With the correct term, I can search for relevant trials comparing it to observation for breast cancer.",,False,
"Find/search the clinical trial id that best describes the efficacy of Paclitaxel and Ramucirumab compared to Paclitaxel monotherapy when used to treat Gastric cancer.
Output it in the format NCT<Number>",NCT02898077,NCT01170663,NCT01170663,False,
"Find/search the clinical trial id that best describes the efficacy of 7 plus 3d and Midostaurin compared to 7 plus 3d when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT00651261,"Based on your description, the pivotal Phase 3 clinical trial that compared 7+3 induction chemotherapy plus Midostaurin versus 7+3 plus placebo in newly diagnosed Acute Myeloid Leukemia patients (specifically those with *FLT3* mutations) is the RATIFY trial.

The clinical trial id is:
NCT00651261",NCT00651261,True,
"Find/search the clinical trial id that best describes the efficacy of FCR compared to Cyclophosphamide and Fludarabine (FC) when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT00090051,NCT00281918,NCT00281918,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Lenalidomide monotherapy when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT01122472,"NCT01122763

This clinical trial (REMARC study) compares Lenalidomide vs. Placebo as maintenance therapy after R-CHOP in elderly patients with Diffuse Large B-cell Lymphoma. It directly evaluates the efficacy of Lenalidomide compared to placebo in this setting.",NCT01122763,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Non-small cell lung cancer (Metastatic).
Output it in the format NCT<Number>",NCT01168973,NCT01164252,NCT01164252,False,
"Find/search the clinical trial id that best describes the efficacy of R-CHOP-14 compared to CHOP-14 when used to treat Diffuse large B-cell lymphoma.
Output it in the format NCT<Number>",NCT00052936,NCT00168452,NCT00168452,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Docetaxel and Ramucirumab when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00703326,"NCT00703326

This trial (ROSE/TRIO-12) is a Phase III study comparing Docetaxel plus Ramucirumab versus Docetaxel plus placebo as first-line therapy for locally recurrent or metastatic breast cancer.",NCT00703326,True,
"Find/search the clinical trial id that best describes the efficacy of Cisplatin, Cetuximab, RT compared to Cisplatin and RT when used to treat Head and neck cancer.
Output it in the format NCT<Number>",NCT00084318,"Based on the search criteria for a clinical trial comparing Cisplatin + Cetuximab + RT versus Cisplatin + RT for Head and Neck Cancer efficacy, the most prominent and relevant trial is:

NCT00265991",NCT00265991,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Rituximab (R2) compared to Rituximab monotherapy when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT01307605,NCT01938001,NCT01938001,False,
"Find/search the clinical trial id that best describes the efficacy of Fulvestrant monotherapy compared to Taselisib and Fulvestrant when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT02340221,"Based on your description, the clinical trial that directly compares Taselisib plus Fulvestrant versus Fulvestrant monotherapy (with placebo) for efficacy in treating advanced breast cancer, particularly focusing on patients with PIK3CA mutations, is the FAKTION study.

The corresponding ClinicalTrials.gov identifier is:

NCT02340221",NCT02340221,True,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Regorafenib monotherapy when used to treat Osteosarcoma.
Output it in the format NCT<Number>",NCT02048371,"The clinical trial ID that best describes the efficacy of Placebo compared to Regorafenib monotherapy when used to treat Osteosarcoma is:

NCT02389316",NCT02389316,False,
"Find/search the clinical trial id that best describes the efficacy of CMF compared to CMF and RT|E-CMF and RT|A-CMF and RT|MMM and RT when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00003893,NCT00003850,NCT00003850,False,
"Find/search the clinical trial id that best describes the efficacy of Bendamustine and Rituximab (BR) compared to Bendamustine and Rituximab (BR) and Ibrutinib when used to treat Chronic lymphocytic leukemia.
Output it in the format NCT<Number>",NCT01776840,NCT02264574,NCT02264574,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Observation when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00376792,"Based on a search of clinical trial databases, finding a large-scale, Phase 3 clinical trial *specifically* comparing Docetaxel monotherapy directly against Observation for efficacy in prostate cancer is not a standard or commonly reported study design, particularly in the metastatic setting where Docetaxel is primarily used for survival benefit.

Docetaxel trials typically compare it to other active treatments, best supportive care, or placebo (often in combination with steroids like prednisone). Observation as a direct comparator arm for chemotherapy efficacy is more common in earlier stage prostate cancer (like watchful waiting or active surveillance for localized disease) or sometimes as part of a ""delayed treatment"" arm.

However, there are trials that *do* include Docetaxel monotherapy compared to an Observation arm, although often in a specific context like the neoadjuvant setting for localized disease.

One such trial that directly fits the description of comparing Docetaxel monotherapy to Observation for efficacy endpoints (like pathologic response, recurrence, survival) is:

**NCT00303338**

**Note:** This is a Phase II trial comparing neoadjuvant Docetaxel vs Observation followed by surgery in patients with intermediate risk localized prostate cancer. While it directly compares Docetaxel monotherapy to Observation and assesses efficacy, it is not a large, definitive trial in metastatic disease where Docetaxel's survival benefit is most established compared to control groups that typically received other agents like prednisone or mitoxantrone. However, it is one of the few trials that precisely matches the requested comparison of ""Docetaxel monotherapy compared to Observation"".",NCT00303338,False,
"Find/search the clinical trial id that best describes the efficacy of EP-T compared to EC-T when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01026116,"Based on the common chemotherapy regimens and searches for clinical trials comparing similar structures involving Epirubicin, Cyclophosphamide, Taxane, and Platinum in Breast Cancer, the trial that best fits the description of comparing a regimen akin to EC-T against one that includes a platinum agent in a similar sequence is the GEPARQUINTO trial.

This trial compared:
*   Arm A: EC (Epirubicin/Cyclophosphamide) followed by Docetaxel (D)
*   Arm B: EC followed by Docetaxel and Carboplatin (DCb)

While not a direct (Epirubicin+Platinum)-Taxane vs (Epirubicin+Cyclophosphamide)-Taxane structure, it directly compared a standard EC-Taxane regimen to one that *added* a Platinum (Carboplatin) to the Taxane phase after the EC, making it a relevant study evaluating the contribution of platinum in the context of an Epirubicin/Cyclophosphamide/Taxane backbone in breast cancer. Efficacy (specifically pathological complete response - pCR) was the primary endpoint.

The clinical trial id for the GEPARQUINTO trial is:

NCT00567122",NCT00567122,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Gefitinib monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT00020709,NCT00029615,NCT00029615,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Gemcitabine monotherapy when used to treat Bladder cancer.
Output it in the format NCT<Number>",NCT00445601,"Based on searches in clinical trial databases, a direct clinical trial specifically comparing the efficacy of Gemcitabine *monotherapy* against Placebo *monotherapy* for the treatment of bladder cancer is highly unusual and difficult to find, particularly for established or advanced disease.

This specific comparison is uncommon because:
1.  For patients with established or advanced bladder cancer, effective standard treatments (often combination chemotherapy like Gemcitabine/Cisplatin) exist, making it ethically questionable to withhold active treatment and assign patients to a Placebo arm as the primary therapy.
2.  Placebo arms in bladder cancer trials are more typically used in:
    *   Maintenance settings *after* initial therapy.
    *   As a control group for a novel agent when that agent is added to a standard backbone therapy (e.g., Standard Therapy + Investigational Drug vs. Standard Therapy + Placebo).

Therefore, a prominent clinical trial with a design comparing **Gemcitabine monotherapy vs. Placebo monotherapy for efficacy** in treating bladder cancer is likely non-existent or extremely rare due to ethical considerations and standard clinical practice.

Without a specific trial matching this exact, uncommon comparison, I cannot provide a relevant NCT number.",,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Estramustine compared to Mitoxantrone and Prednisone when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00004001,NCT00003134,NCT00003134,False,
"Find/search the clinical trial id that best describes the efficacy of Best supportive care compared to Trabectedin monotherapy when used to treat Soft tissue sarcoma.
Output it in the format NCT<Number>",NCT02672527,NCT00174278,NCT00174278,False,
"Find/search the clinical trial id that best describes the efficacy of Everolimus and Tamoxifen compared to Tamoxifen monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01298713,NCT00559421,NCT00559421,False,
"Find/search the clinical trial id that best describes the efficacy of Carboplatin and Paclitaxel (CP), Bevacizumab, Nivolumab compared to Carboplatin and Paclitaxel (CP) and Bevacizumab when used to treat Non-small cell lung cancer nonsquamous.
Output it in the format NCT<Number>",NCT03117049,"Based on a search for clinical trials investigating the combination of Carboplatin, Paclitaxel, Bevacizumab, and Nivolumab in non-small cell lung cancer, the trial that best describes the evaluation of efficacy for the experimental arm containing all four drugs, although not necessarily against the exact control arm requested (which specifically omits Nivolumab), is:

NCT03136489",NCT03136489,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel monotherapy compared to Paclitaxel monotherapy when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00002662,NCT00003832,NCT00003832,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to Docetaxel monotherapy when used to treat Non-small cell lung cancer.
Output it in the format NCT<Number>",NCT01038661,NCT00041072,NCT00041072,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to IRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01564537,NCT01850524,NCT01850524,False,
"Find/search the clinical trial id that best describes the efficacy of Lenalidomide and Dexamethasone (Rd) compared to IRd when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT01850524,"Based on clinical trial data, the pivotal Phase 3 trial that directly compared Ixazomib plus Lenalidomide and Dexamethasone (IRd) to Lenalidomide and Dexamethasone (Rd) in relapsed/refractory multiple myeloma was TOURMALINE-MM1.

The clinical trial id for this study is:
NCT01564537",NCT01564537,False,
"Find/search the clinical trial id that best describes the efficacy of Docetaxel and Trastuzumab (TH)|Paclitaxel and Trastuzumab (TH) compared to Vinorelbine and Trastuzumab (VH) when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT00146549,NCT00094037,NCT00094037,False,
"Find/search the clinical trial id that best describes the efficacy of Observation compared to CVP when used to treat Follicular lymphoma.
Output it in the format NCT<Number>",NCT00115700,"Based on a search of clinical trial databases for studies comparing Observation (Watch and Wait) to CVP (Cyclophosphamide, Vincristine, Prednisone) in treating Follicular Lymphoma and assessing efficacy, a prominent trial that includes this specific comparison is:

NCT00003274",NCT00003274,False,
"Find/search the clinical trial id that best describes the efficacy of Azacitidine monotherapy compared to Azacitidine and Venetoclax when used to treat Acute myeloid leukemia.
Output it in the format NCT<Number>",NCT02993523,NCT02993406,NCT02993406,False,
"Find/search the clinical trial id that best describes the efficacy of Placebo compared to Aspirin monotherapy when used to treat Venous thromboembolism.
Output it in the format NCT<Number>",NCT00222677,NCT00149448,NCT00149448,False,
"Find/search the clinical trial id that best describes the efficacy of T-DM1 and ET compared to Trastuzumab and ET when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01817452,"Based on your description, the clinical trial that directly compared T-DM1 in combination with Endocrine Therapy (ET) to Trastuzumab in combination with ET for HER2-positive, hormone receptor-positive advanced breast cancer is:

NCT01761132",NCT01761132,False,
"Find/search the clinical trial id that best describes the efficacy of VAD compared to Z-Dex when used to treat Multiple myeloma.
Output it in the format NCT<Number>",NCT00006232,"Based on my search and understanding of standard multiple myeloma treatment regimens, it is highly unlikely that a clinical trial exists that directly compares the *efficacy* of **VAD** (Vincristine, Doxorubicin, Dexamethasone) head-to-head against **Z-Dex** (Zometa/Zoledronic Acid, Dexamethasone) as primary anti-myeloma therapy.

Here's why:
1.  **VAD** is a chemotherapy-based regimen primarily aimed at killing myeloma cells directly.
2.  **Zometa (Zoledronic Acid)** is a bisphosphonate used primarily to prevent bone complications (like fractures and pain) associated with multiple myeloma. While bisphosphonates might have some indirect anti-myeloma effects, they are not typically used as the main therapy *instead* of chemotherapy or novel agents.
3.  **Dexamethasone** is a steroid used in both regimens and is an active anti-myeloma agent, but Zometa+Dex alone would not be considered equivalent in terms of tumor burden reduction compared to a multi-drug regimen like VAD.

Clinical trials comparing treatments for multiple myeloma typically compare regimens with similar goals (e.g., VAD vs. novel agents like bortezomib-dex or lenalidomide-dex, or different combinations of chemotherapy/novel agents). A comparison between a cytotoxic regimen (VAD) and a supportive care drug combined with a steroid (Zometa+Dex) for primary efficacy would not be a standard or informative trial design.

Therefore, I cannot provide an NCT number for a trial that directly compares the efficacy of VAD vs. Z-Dex because such a trial is not typically conducted.",,False,
"Find/search the clinical trial id that best describes the efficacy of ddT-ddEC compared to nP-ddEC when used to treat Breast cancer.
Output it in the format NCT<Number>",NCT01779206,NCT01780528,NCT01780528,False,
"Find/search the clinical trial id that best describes the efficacy of ADT and Zoledronic acid compared to ADT when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT00685646,"Based on the description, the clinical trial that best fits the comparison of ADT and Zoledronic acid combined versus ADT alone for efficacy in prostate cancer, particularly in the high-risk or advanced setting, is:

NCT00268476",NCT00268476,False,
